Case-Based Roundtable®

This roundtable series reviews the use of treatments targeting EGFR mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.

This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.

This roundtable series assesses the use of Bruton tyrosine kinase inhibition for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, as discussed by participants at virtual live events.

This roundtable series presents physicians' views on how to treat a patient with locally advanced or metastatic HER2-positive gastric cancer, as discussed by participants at virtual live events.

This roundtable series reflects on the management of patients with myeloproliferative neoplasms and JAK mutations, from biopsy and diagnosis to the use of JAK inhibition as treatment, as discussed by participants at virtual live events.

This roundtable series delves into therapies used for limited-stage small cell lung cancer or early-stage non–small cell lung cancer, as discussed by participants at virtual live events.

This roundtable series reviews the use of B-cell maturation antigen–targeted treatments in patients with relapsed/refractory multiple myeloma, as discussed by participants at virtual live events.

This roundtable series considers the use of CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer as discussed by participants at virtual live events.

This roundtable series delves into therapies used for late-stage small and non–small cell lung cancer as discussed by participants at virtual live events.

This roundtable series examines PARP inhibition as first-line maintenance therapy for patients with advanced ovarian cancer as discussed by participants at virtual live events.

This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.

This roundtable series assists in the evaluation of multiple lines of therapies for patients with metastatic breast cancer as discussed by participants at virtual live events.

This roundtable series reviews the selection of regimens for patients with HER2-positive breast cancer as discussed by participants at virtual live events.

This roundtable series provides insight on risk assessment and multiple therapy combinations for patients with advanced renal cell carcinoma as discussed by participants at virtual live events.

This roundtable series evaluates genomic testing and NTRK-targeted treatment in patients with thyroid cancer as discussed by participants at virtual live events.

This roundtable series covers tyrosine kinase inhibition in the first line for patients with hepatocellular carcinoma discussed in virtual live events.

This roundtable series explores therapies for patients with castration-sensitive prostate cancer discussed in virtual live events.

This roundtable series assesses the use of treatments targeting MET exon 14 skipping mutations in patients with non–small cell lung cancer discussed in virtual live events.

This roundtable series reviews the use of Bruton’s tyrosine kinase inhibition as front-line treatment for patients with chronic lymphocytic leukemia discussed in virtual live events.

This roundtable series explores the use of later-line therapies in patients with diffuse large B-cell lymphoma discussed in virtual live events.

This roundtable series covers molecular imaging, prostate-specific membrane antigen testing, and treatment options for patients with castration-resistant prostate cancer discussed in virtual live events.